The OPTION trial evaluated IV tenecteplase (0.25 mg/kg) in CT perfusion–selected non-LVO ischemic stroke patients treated 4.5–24 hours after last-known-well. Tenecteplase improved excellent 90-day outcomes (mRS 0–1) but increased symptomatic intracranial hemorrhage, with the benefit–harm balance sensitive to outcome and ...
In this special episode of Rebel Cast, we spotlight the Incrementum Conference in Spain, a significant event in emergency medicine. Hosts welcome Dr. Francisco 'Paco' Campillo Palma and Dr. Carmen Maria Cano, founders of Incrementum, to discuss the recognition of ...
Managing patients with suspected occult scaphoid fractures and normal X-rays presents a common clinical dilemma. About 1 in 10 of these patients will have an occult fracture, and roughly 10% of all scaphoid fractures result in nonunion. However, the risk ...
Current IDSA guidelines for sepsis recommend individualized durations of antibiotic therapy based on source control and clinical response, but definitive guidance remains limited. Three small noninferiority RCTs suggested that 7 days of antibiotics may be sufficient for patients with gram-negative ...
Introduction: In this episode of Rebel Cast, host Marco Propersi, along with co-hosts Steve Hochman and Kim Baldino, delve into the practice and importance of street medicine—the direct delivery of healthcare to homeless and unsheltered individuals. Special guests Dr. Jim ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
